Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab vs Chemotherapy in Stage IV Nonsquamous NSCLC
NCT03830411Phase 2Unknown
- Start
- Mar 2019
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms). Primary endpoint: Overall Survival at 21 months. Status: unknown.
02
Drugs
sintilimab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03830411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03830411.